Breast Cancer | Specialty

Genetic Tests Offer New Tool for Tumor Assessment

February 25th 2015

Pathology, Oncology Collaboration in Breast Cancer

February 25th 2015

Predicting Risk of Recurrence in Breast Cancer

February 25th 2015

Reviewing Key Genomic Assays in Breast Cancer

February 25th 2015

Pathologist's Role in Genetic Testing for Breast Cancer

February 25th 2015

Role of Genetic Testing in Breast Cancer

February 25th 2015

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Swain Discusses Final Survival Analysis of CLEOPATRA Study

February 24th 2015

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

Unprecedented OS Benefit Cements Pertuzumab Regimen as Frontline Standard in HER2-Positive MBC

February 20th 2015

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

Slamon's Tenacity Advances the Field of Breast Cancer Research

February 19th 2015

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Chemobrain-It's Real, It's Complex, and the Science Is Still Evolving

February 17th 2015

Talk with almost any cancer survivor, and she/he is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory.

Lung Cancer Screening, Trabectedin in Soft Tissue Sarcoma, and More

February 12th 2015

Palbociclib: An Exciting New Option in Breast Cancer

February 12th 2015

Integrating Palbociclib Into the Treatment of Breast Cancer

February 12th 2015

Preclinical and Clinical Evidence Supporting Palbociclib

February 12th 2015

SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer

February 9th 2015

Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.

Latest News & Insight: February 5, 2015

February 6th 2015

Dr. Shih on Treating Lobular vs Ductal Breast Cancers

February 5th 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer

February 4th 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.